Redhill Biopharma (STU:2RH) Interest Expense: €-0.03 Mil (TTM As of Dec. 2025)


STU:2RH Redhill Biopharma Ltd STU:2RH
18 GF Score
Price €8.24
! 6 Warning Signs
View Full Analysis

What is Redhill Biopharma Interest Expense?

Redhill Biopharma STU:2RH 18 Interest Expense is €-0.03 Mil as of Dec. 2025. GuruFocus rates STU:2RH with a GF Score™ of 18/100. The stock has 6 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Redhill Biopharma's interest expense for the six months ended in Dec. 2025 was € 0.92 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.03 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Redhill Biopharma's Operating Income for the six months ended in Dec. 2025 was € -3.02 Mil. Redhill Biopharma's Interest Expense for the six months ended in Dec. 2025 was € 0.92 Mil. Redhill Biopharma did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Redhill Biopharma  (STU:2RH) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Redhill Biopharma's Interest Expense for the six months ended in Dec. 2025 was €0.92 Mil. Its Operating Income for the six months ended in Dec. 2025 was €-3.02 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2025 was €0.77 Mil.

Redhill Biopharma's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Redhill Biopharma Interest Expense Historical Data

* Premium members only.

The historical data trend for Redhill Biopharma's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Redhill Biopharma Interest Expense Chart

Redhill Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -14.66 -39.02 -0.06 -0.04 -0.02

Redhill Biopharma Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.09 -1.67 1.67 -0.95 0.92
STU:2RH
18GF Score
Redhill Biopharma Ltd STU:2RH
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Redhill Biopharma Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of €-0.03 Mil mean?
Redhill Biopharma (STU:2RH) has a Interest Expense of €-0.03 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Redhill Biopharma and its competitors.
Is Redhill Biopharma's Interest Expense too high?
Redhill Biopharma's current Interest Expense is €-0.03 Mil. Overall, Redhill Biopharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Redhill Biopharma's Interest Expense compare to SBFM and PRFX?
Redhill Biopharma's Interest Expense of €-0.03 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Redhill Biopharma and its competitors. Redhill Biopharma's current Interest Expense is €-0.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Redhill Biopharma stock overvalued right now?
Redhill Biopharma (STU:2RH) has a current Interest Expense of €-0.03 Mil. The current Interest Expense is €-0.03 Mil. Redhill Biopharma's overall GF Score™ is 18/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Redhill Biopharma (STU:2RH), the current Interest Expense is €-0.03 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Redhill Biopharma Business Description

Other Exchanges RDHL:USA
Address 21 Ha’arba’a Street, Tel Aviv, ISR, 6473921
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.
18GF Score

Get the complete analysis for STU:2RH

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.24
Price